Macrophages increase and are highly activated in chronic obstructive pulmonary disease (COPD). Muscarinic receptor antagonists inhibit acetylcholine stimulatedrelease of neutrophilic chemoattractants suggesting that acetylcholine may regulate macrophage responses. Therefore, expression and function of components of the non-neuronal cholinergic system in monocyte-macrophage cells was investigated. 
Background
Macrophages are the predominant inflammatory cell found in the lung. Their role is primarily to remove any inhaled particles and pathogens and maintain sterility of the respiratory tract. However, in lung diseases such as chronic obstructive pulmonary disease (COPD), macrophage numbers increase by more than ten-fold and are highly activated producing increased levels of inflammatory mediators [1] . At present, pharmacotherapy for COPD is largely symptomatic with no treatments capable of decreasing the underlying inflammatory response and improving lung function [2] .
Long acting muscarinic antagonists such as tiotropium bromide have been shown to have efficacy in patients with COPD [3] although whether this drug could also act to control the inflammatory components of the disease or act upon the small airways where COPD is manifest is unclear. Recently, tiotropium bromide has been shown to suppress chemotactic activity released by macrophages following stimulation with acetylcholine (ACh) [4] . This suggests that macrophage mediated inflammation may, in part, be regulated by components of the non-neuronal cholinergic system. Classically, ACh is synthesised in nerve terminals and is released to regulate many activities including regulation of airway contraction and dilation of vessels [5, 6] .
More recently, essential components of the non-neuronal cholinergic system, including the high-affinity choline transporter (CHT1), ACh, choline acetyltransferase (ChAT), and muscarinic and nicotinic ACh-receptors are expressed by a number of non-neuronal cells including peripheral blood mononuclear cells (PBMC) and lymphocytes [7, 8] . Many of these cells, not only release ACh upon stimulation but also can be activated by ACh [9 -11] . Bovine alveolar macrophages release neutrophil, monocyte and eosinophil chemotactic factors after stimulation with ACh [12] and it has been suggested that human alveolar macrophages release leukotriene (LT)B 4 in response to ACh stimulation [4] . Cells obtained from induced sputum have been also been shown to express muscarinic M 2 and M 3 receptors and that following stimulation with ACh increased the release of LTB 4 in cells from COPD patients but not cells from non-smokers or smokers [13] . Taken together, these data suggest that non-neuronal ACh might be involved in the pathophysiology of COPD by stimulating the release of inflammatory mediators from macrophages.
This study examined the expression of components of the non-neuronal cholinergic system including CHT1, ChAT and vesicular acetylcholine transporter (VAChT) in cells of the monocyte-macrophage lineage together with expression of muscarinic receptors (M [1] [2] [3] [4] [5] ). The putative roles of these receptors on macrophages were then evaluated using functional assays.
Methods

Subject Selection
Subjects were recruited from clinics at the Royal Brompton Hospital NHS Trust, from staff of the Royal Brompton Hospital and National Heart & Lung Institute, or volunteers known to the clinical research group of the Asthma Laboratory, National
Heart & Lung Institute. Alveolar macrophages from BAL fluid of non-smokers, smokers and patients with COPD were obtained from consenting patients at Heatherwood Hospital, Ascot, Wexham Park Hospital, Slough. Smokers had a smoking history of at least 10 pack years and COPD patients were stable and fulfilled the American Thoracic Society criteria [14] . All studies were approved by the Ethics Committee of Royal Brompton and Harefield NHS Trust and National Heart and Lung Institute Ethics Committee, the East Berkshire Local Research Ethics Committee or St Mary's NHS Trust Ethics Committee. All subjects gave informed written consent.
Preparation of monocytes
Monocytes were isolated from peripheral blood, centrifuged on discontinuous Percoll gradients, and purified either by adherence to tissue culture plastic [15] or by negative immunoselection using a MACS monocyte isolation kit (Miltenyi Biotec; Bisley, UK) and magnetic depletion columns according to the manufacturer's instructions. Cells were cultured in complete media (RPMI-1640 media supplemented with 10% (v/v) foetal calf serum (FCS), 100 U/ml penicillin, 100 g/ml streptomycin and 2mM L-glutamine) in a 6-well plate and were then resuspended in lysis buffer and stored at -70C.
Preparation of Monocyte-Derived Macrophages
After separation of PBMC, cells were resuspended at 2 x 10 6 cells/ml in complete media. The cells were seeded onto 48 well plates, or chamber slides and incubated for 2 h at 37C in a humidified incubator with 5% (v/v) CO 2 . After incubation the supernatant was removed and replaced with complete media supplemented with 2ng/ml GM-CSF. The cells were differentiated in culture for 12 d towards a macrophage phenotype.
Preparation of Lung-Derived Macrophages
Lung-derived macrophages were isolated from lung tissue as previously described [16] . Briefly, lung tissue from patients undergoing surgical resection for carcinoma was lavaged by injection of RPMI-1640 containing 100 U/ml penicillin, 100 g/ml CO 2 , the non-adherent cells were removed and fresh medium was added. The adherent purified macrophages were incubated overnight and the medium was changed the next day before beginning the experiment. Macrophage purity was confirmed by anti-CD68 staining as described previously [17] .
Preparation of Alveolar Macrophages
Bronchoscopy and processing were performed according to the guidelines of the European Respiratory Society (ERS) task force [18] and alveolar macrophages isolated as described previously [19] .
Preparation of Sputum Cells
Sputum was induced by inhalation of hypertonic saline and processed with 0.05%
(w/v) dithiothreitol [20] . After centrifugation, the cell pellet was resuspended with HBSS and cytospins prepared.
Real-time PCR
Total RNA was extracted from cells using an RNeasy RNA extraction kits (Qiagen, Crawley, UK) and isolated RNA was quantified using the Ribogreen quantification Assay (Molecular Probes; Leiden, Netherlands). RNA was reverse transcribed using analysed on the same plate, calculated using extrapolation of standard curve values.
Immunocytochemisty of M 2 and M 3 receptors
Slides were immersed for 10 min with 4% (wt/vol) paraformaldehyde in PBS (pH 7.4).
After washing with PBS, the slides were incubated with either rabbit anti-human 
Measurement of IL-8 and IL-6 using ELISA
IL-8 and IL-6 were measured in the supernatants from MDM and tissue-derived macrophage incubated with ACh or carbachol using enzyme-linked immunosorbent assay (ELISA) (R&D Systems, Abingdon, UK). Lower limit of detection of this assay was 16pg/ml for both assays.
Measurement of LTB 4
Release of LTB 4 into cell culture media was measured using a commercially available kit from GE Healthcare (Buckinghamshire, UK) according to the manufacturer's instructions.
Measurement of ACh release
Release of ACh into the cell culture media was measured using a commercially available kit from Invitrogen Ltd., (Paisley, Scotland, UK), according to the manufacturer's instructions. Lower limit of detection of this assay is 1.5µM.
Cell viability assays
Cell viability was determined colourimetrically by measuring the reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide, MTT, to formazan by mitochrondial dehydrogenases, as described previously [21] . None of the cell treatments altered cell viability.
Statistical Analysis
GraphPad Prism (GraphPad Software Inc., San Diego, California) was used to perform all statistical tests. When the data were analysed non-parametric distribution was assumed therefore the Wilcoxon matched paired test or Kruskal-Wallis test was used initially with Dunns' post test for ANOVA analysis. Results were considered significant when p<0.05.
Results
Expression of components of the ACh synthesis pathway
In order to examine whether cells of the monocyte-macrophage have the capacity to synthesise ACh, the expression of components of the ACh synthesis pathway, CHT1,
ChAT and VAChT were examined by real-time PCR. All three components were expressed by monocytes, MDM, lung macrophages and alveolar macrophages (Table 1 ). There was no difference in the level of expression of any of the components of the ACh synthesis pathway in any of the cells examined with the exception of significantly reduced expression of ChAT in lung macrophages (Table 1) .
Low levels of ACh were released and could be measured from lung macrophages (6±2µM, n=4), however these levels were near the limit of detection of the assay.
Muscarinic Receptor Expression Analysed by Real-Time PCR
Having ascertained that cells of the monocyte-macrophage lineage express mRNA for proteins to drive synthesis of ACh, we next determined whether these cells could respond to this mediator. To this end, we examined the level of mRNA expression of 42.1, (32, 90)%, n=13) (Fig 1c) .
M 2 and M 3 receptor expression estimated by Immunohistochemistory
In order to confirm the expression data obtained using Taqman analysis regarding the expression of muscarinic receptors in cells of the monocyte/macrophage lineage, we performed immunocytochemistry. Due to the poor quality and availability of antibodies against human muscarinic receptors, this study was limited to expression of M 2 and M 3 receptors. M 2 and M 3 receptor expression was evaluated on MDM and lung-derived macrophages (Fig 2) with the M 2 receptor predominant on the cell membrane. Expression of the M 3 receptor on MDM appeared to be both membraneassociated and cytosolic (Fig 2) . In lung-derived macrophages expression of M 2 and M 3 receptors was also detected on the cell membrane (Fig 2a) . The immunocytochemistry was validated using FACS (Fig 2b) , where M 2 expression was observed on 50.8±17.3% of lung macrophages with an MFI of 5.4±1.2, n=5 and M 3 expression was observed on 66.5±17.3% of lung macrophages with an MFI of 6.9±1.3, n=5. Expression was also determined in cells obtained from BAL and sputum samples from non-smokers, smokers and patients with COPD. Cells obtained from BAL from all three groups expressed similar levels of both M 2 and M 3 receptor (Fig. 3) , with expression associated with the macrophages. Similarly, macrophages obtained from induced sputum expressed similar levels of the M 2 receptor (Fig 4) with less expression of the M 3 receptor (Fig 4) . In order to investigate the mechanism of carbachol-stimulated LTB 4 
Function of muscarinic receptors on MDM and lung-derived macrophages
Discussion
This study demonstrated that mRNA for components of the ACh synthesis pathway were expressed by both monocytes and macrophages. Human mononuclear cells have been reported to contain ACh [22] and ChAT is expressed by rat monocytes [23] and human alveolar macrophages [24] , however we have now demonstrated expression of CHT1 and VAChT in cells of the monocyte-macrophage lineage suggesting that these cells are capable of ACh synthesis and release of ACh from lung macrophages could be measured, but were very low and near to the limit of detection of the assay. Nevertheless, ACh may reach sufficient concentrations to act locally and thus contribute to the inflammatory response. This is further substantiated by expression of muscarinic receptor mRNA in cells of the monocyte-macrophage
lineage.
The present study demonstrated expression of mRNA for muscarinic M 1 -M 5 receptors in human monocytes in contrast to a previous report [25] . This may reflect increased sensitivity of real-time PCR methodology. However, the present study showed increased expression of M 1 , and M 3 mRNA in lung derived macrophages compared with monocytes. This may suggest that as monocytes differentiate towards a macrophage phenotype there is a concomitant change in expression of muscarinic receptors. However, lung tissue macrophages were obtained from the tissue of patients undergoing surgery for lung cancer. Although, the tissue was macroscopically normal, it is not known whether the tumour promoting environment may alter the expression of muscarinic receptors locally. Nevertheless, these data are consistent with reports of M 3 receptor expression in alveolar macrophages [12, 13] and were further substantiated with immunocytochemistry. Using this technique, it was observed that despite little difference between MDM and lung macrophages with respect to M 2 mRNA expression, there appeared to be increased protein expression in the MDM. Similarly, despite lung derived macrophages expressing significantly greater quantities of M 3 mRNA compared with MDM, protein expression by immunocytochemistry appeared reduced. This suggests that mRNA levels of muscarinic receptors may not reflect protein expression in these cell types.
To address this further, we used FACS analysis of lung macrophage expression of receptor. Therefore, antagonists of the M 3 receptor might contribute to the control of inflammatory status such as the release of LTB 4 from macrophages in addition to the inhibitory effect of smooth airway contraction and suggest an additional role for these drugs in COPD and other inflammatory lung diseases [28] . 
